Zetia vs Lisinopril Head-to-Head Efficacy: What the Clinical Evidence Actually Shows

Why a Direct Head-to-Head Trial Does Not Exist

No randomized controlled trial has enrolled patients to receive ezetimibe versus lisinopril as competing interventions. That absence is not an oversight. The two drugs treat distinct physiological problems, and randomizing a hypertensive patient away from antihypertensive therapy, or a hypercholesterolemic patient away from lipid-lowering therapy, would be unethical under current guidelines.

Clinicians and patients searching for "Zetia vs lisinopril head-to-head efficacy" are often asking a practical question: which one do I need, or do I need both? The answer requires understanding what each drug actually does at the mechanistic and outcomes level, then matching that to individual risk factors.

How Ezetimibe Works

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal epithelium, blocking the absorption of both dietary and biliary cholesterol. The resulting reduction in hepatic cholesterol uptake prompts upregulation of LDL receptors, which then pull more LDL particles out of circulation. As monotherapy, ezetimibe reduces LDL-C by roughly 18-20% [1]. When added to a moderate-intensity statin, the incremental LDL-C reduction is an additional 23-24 percentage points on top of what the statin achieves alone [2].

How Lisinopril Works

Lisinopril is a long-acting ACE inhibitor. It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. The net effect is lower peripheral vascular resistance and, in most patients, a reduction in systolic blood pressure of 10-15 mmHg from baseline [3]. Lisinopril also reduces proteinuria through reduced intraglomerular pressure, which is why it carries a Class I indication for diabetic nephropathy in the 2023 ACC/AHA Hypertension Guidelines [4].

IMPROVE-IT: The Defining Evidence for Ezetimibe

IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) is the largest outcomes trial for ezetimibe to date. Published in the New England Journal of Medicine in 2015, it enrolled 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL-C between 50 and 100 mg/dL on statin therapy [1].

Trial Design and Primary Endpoint

Patients were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (90 or more days after randomization), or nonfatal stroke. Median follow-up was 6 years.

Key Outcomes Numbers

The simvastatin-ezetimibe group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-placebo group, a difference of 15.8 mg/dL. The primary endpoint occurred in 32.7% of patients in the ezetimibe group and 34.7% in the placebo group, translating to a hazard ratio of 0.936 (95% CI 0.89-0.99, P<0.001 for non-inferiority and P=0.016 for superiority) [1]. That is the 6.4% relative risk reduction cited widely in the literature. Absolute risk reduction was 2 percentage points over 7 years, yielding a number needed to treat (NNT) of 50.

The trial also demonstrated that lower LDL-C was consistently better, reinforcing the "lower is longer" principle now embedded in the 2022 ACC Expert Consensus Decision Pathway on statins [5].

What IMPROVE-IT Does Not Tell Us

IMPROVE-IT says nothing about blood pressure. Patients with uncontrolled hypertension were not excluded, but the intervention was lipid-specific. Any blood-pressure-related outcomes in the trial reflect usual care, not a randomized comparison of antihypertensive strategies.

ALLHAT: The Defining Evidence for Lisinopril (and Its Limitations)

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is the largest randomized antihypertensive trial ever conducted, with 33,357 participants aged 55 or older who had hypertension plus at least one additional coronary heart disease risk factor [6].

Trial Design

ALLHAT compared four antihypertensive strategies: chlorthalidone (a thiazide-type diuretic), amlodipine (a calcium channel blocker), lisinopril (an ACE inhibitor), and doxazosin (an alpha-blocker, which was terminated early). The primary outcome was combined fatal coronary heart disease or nonfatal MI. Mean follow-up was 4.9 years.

Lisinopril Versus Chlorthalidone: Where the Drug Fell Short

For the primary outcome (fatal CHD and nonfatal MI), lisinopril performed equivalently to chlorthalidone (relative risk 0.99, 95% CI 0.91-1.08) [6]. That is a neutral result, not a failure. The more clinically important finding: stroke incidence was 15% higher in the lisinopril group compared to the chlorthalidone group (relative risk 1.15, 95% CI 1.02-1.30, P=0.02) [6]. Lisinopril also showed significantly higher rates of combined cardiovascular disease and hospitalized or treated heart failure compared to chlorthalidone [6].

The ACC/AHA 2017 Hypertension Guidelines address this directly, noting that thiazide-type diuretics remain preferred first-line therapy for most patients, with ACE inhibitors reserved for patients with compelling indications such as diabetes, chronic kidney disease, or prior MI [4].

Where Lisinopril Excels

Despite the stroke signal versus a diuretic, lisinopril's benefit in specific populations is well-established. The HOPE trial (N=9,297) showed that ramipril (a closely related ACE inhibitor) reduced MI, stroke, and cardiovascular death by 22% relative to placebo in high-risk patients without left ventricular dysfunction, many of whom had normal blood pressure at baseline [7]. ACE inhibitors as a class, including lisinopril, remain first-line for patients with heart failure with reduced ejection fraction (HFrEF) under the 2022 AHA/ACC Heart Failure Guidelines [8].

Comparing Mechanisms and Outcomes Side by Side

Because these drugs target entirely different physiological pathways, the most useful comparison is not "which is better" but "which addresses the specific risk factor driving cardiovascular harm in this patient."

LDL-C Reduction vs Blood Pressure Control

Cardiovascular risk scales with both LDL-C and systolic blood pressure, but they are independent contributors. A 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C reduces major vascular events by about 22% [9]. A 10 mmHg reduction in systolic blood pressure reduces stroke risk by roughly 27% and coronary heart disease by about 17% [10]. The two reductions are additive, not redundant.

Ezetimibe, producing an LDL-C reduction of 18-20 mg/dL as monotherapy, does not lower blood pressure by any clinically meaningful degree. Lisinopril, producing a systolic blood pressure reduction of 10-15 mmHg, has no direct effect on LDL-C.

A patient with isolated hypercholesterolemia and normal blood pressure has no physiological reason to expect blood pressure benefit from ezetimibe. A patient with isolated hypertension and normal LDL-C would gain nothing from lisinopril in the lipid domain.

Side Effect Profiles: Genuinely Different

Ezetimibe's most common adverse effects are diarrhea (reported in approximately 4.1% of patients in clinical trials) and upper respiratory tract infections [11]. Rare cases of myopathy have been reported, primarily when ezetimibe is combined with a statin. No potassium changes, no cough, no renal function changes attributable to ezetimibe alone.

Lisinopril carries a class-specific dry cough in roughly 10-15% of patients due to bradykinin accumulation, which is often the reason patients request a switch to an angiotensin receptor blocker (ARB) such as losartan [4]. Hyperkalemia is a real risk in patients with CKD or in those on potassium-sparing agents. Angioedema, though rare (0.1-0.5%), is potentially life-threatening and is more common in Black patients [6].

A Clinical Decision Framework: Which Drug Fits Which Patient

The following decision structure reflects current ACC/AHA guideline recommendations, not a head-to-head trial result.

Use ezetimibe when:

• LDL-C remains above the patient's risk-stratified goal despite maximally tolerated statin therapy
• The patient is statin-intolerant and needs additional LDL-C lowering beyond diet alone
• Post-ACS, to push LDL-C below 55 mg/dL per the 2022 ACC Expert Consensus [5]
• Cost is a barrier to PCSK9 inhibitor therapy (ezetimibe is available generically for under $10 per month in most US pharmacies)

Use lisinopril when:

• Systolic blood pressure exceeds 130 mmHg with a compelling indication (diabetes, CKD, HFrEF, post-MI)
• The patient needs heart failure mortality reduction
• Proteinuria reduction is a treatment target in diabetic or non-diabetic CKD
• An ARB is not preferred due to tolerability or cost

Use both when:

• The patient has elevated LDL-C and hypertension simultaneously, which describes a large fraction of patients with metabolic syndrome or type 2 diabetes

What Current Guidelines Say About Each Drug

ACC/AHA on LDL-C Lowering with Ezetimibe

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol places ezetimibe as a Class IIa recommendation for patients with clinical ASCVD who are on maximally tolerated statin therapy but remain above their LDL-C goal [12]. The guideline states: "In patients with clinical ASCVD, if LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe therapy." That language reflects the IMPROVE-IT data directly.

ACC/AHA on Lisinopril and ACE Inhibitors

The 2017 ACC/AHA Hypertension Guideline gives ACE inhibitors a Class I recommendation for hypertensive patients with heart failure, stable ischemic heart disease, diabetes mellitus, or CKD [4]. For patients without these compelling indications, thiazide-type diuretics, calcium channel blockers, and ACE inhibitors are listed as equally acceptable first-line agents, though ALLHAT data tend to push most clinicians toward thiazide-type diuretics or CCBs as initial monotherapy.

Can You Take Zetia and Lisinopril Together?

Yes. There is no known pharmacokinetic interaction between ezetimibe and lisinopril. Ezetimibe is metabolized by glucuronidation in the intestine and liver; lisinopril is not significantly metabolized and is excreted unchanged by the kidneys. The two drugs occupy entirely different biochemical spaces.

Patients with mixed dyslipidemia and hypertension are frequently prescribed both agents, often alongside a statin and sometimes a thiazide diuretic or CCB. The 2023 ACC/AHA Guideline for Chronic Coronary Disease specifically endorses aggressive multi-drug cardiometabolic management in patients with established coronary disease [13].

Monitoring requirements differ, though. Patients on ezetimibe need periodic fasting lipid panels to confirm LDL-C response. Patients on lisinopril need periodic serum creatinine, eGFR, and potassium checks, particularly in the first 4 weeks after initiation and after any dose increase or intercurrent illness that could alter renal perfusion.

Cost, Access, and Practical Prescribing Considerations

Generic ezetimibe (10 mg tablets) became available in the United States in 2017 after patent expiration of Zetia. As of 2024, cash-pay prices at major pharmacy chains run approximately $8-15 for a 30-day supply using discount programs such as GoodRx. Lisinopril has been generic for decades; 10 mg tablets are available for under $5 for a 30-day supply at most large pharmacies.

Brand-name Zetia still commands approximately $350-400 per month without insurance. Most pharmacy benefit plans tier generic ezetimibe at Tier 1 or Tier 2, making it accessible for the majority of commercially insured patients.

Prior authorization is rarely required for either generic formulation. However, if a prescriber is considering adding a PCSK9 inhibitor after ezetimibe failure, prior authorization is almost universal and typically requires documentation of a 3-month trial of maximally tolerated statin plus ezetimibe with LDL-C remaining above goal.

Special Populations: Where the Choice Becomes More Nuanced

Patients with Diabetes

Patients with type 2 diabetes frequently have both elevated LDL-C and hypertension. Both drugs carry strong guideline support in this population. Ezetimibe provides additive LDL-C lowering on top of statin therapy. Lisinopril reduces urinary albumin excretion independent of blood pressure reduction, a benefit documented in the UKPDS study and confirmed in multiple meta-analyses [14].

Patients with Chronic Kidney Disease

Lisinopril slows CKD progression in patients with proteinuria, but requires careful monitoring because reduced GFR slows lisinopril's renal excretion and increases hyperkalemia risk. Ezetimibe requires no dose adjustment in any stage of CKD [11].

Patients Post-Acute Coronary Syndrome

IMPROVE-IT was conducted entirely in post-ACS patients. Ezetimibe's 6.4% relative MACE reduction is most confidently applicable to this population. Lisinopril (or any ACE inhibitor) is also guideline-recommended post-MI in patients with reduced ejection fraction, so both drugs often appear on the same post-discharge medication list.

Elderly Patients

Lisinopril requires caution in elderly patients with orthostatic hypotension or volume depletion. Ezetimibe carries no significant age-related restrictions. The SHARP trial (N=9,270), which included patients with CKD across a wide age range, showed that simvastatin plus ezetimibe reduced the risk of major atherosclerotic events by 17% (relative risk 0.83, 95% CI 0.74-0.94, P=0.0022) without excess adverse events in older subgroups [2].

The Bottom Line on Efficacy

"Better" has no meaning when the two drugs are solving different problems. Ezetimibe is better at lowering LDL-C. Lisinopril is better at lowering blood pressure and reducing proteinuria. Neither outperforms the other in the other's domain because neither attempts to act there.

The IMPROVE-IT trial established that a 15.8 mg/dL additional LDL-C reduction with ezetimibe added to a statin translates into a statistically significant, if modest, reduction in MACE over 6 years in post-ACS patients [1]. The ALLHAT trial established that lisinopril is broadly equivalent to chlorthalidone for preventing coronary events but may underperform in stroke prevention, making diuretics a reasonable first choice in patients without compelling indications for an ACE inhibitor [6].

Patients asking "is Zetia better than lisinopril?" should reframe the question as: what is my specific cardiometabolic risk factor target? A physician reviewing your lipid panel, blood pressure readings, kidney function, and prior cardiovascular history will point to one or both of these agents based on where your personal risk lies, not based on any head-to-head trial that does not exist.

If your LDL-C exceeds 70 mg/dL on a maximally tolerated statin and you have documented ASCVD, the ACC/AHA 2018 Cholesterol Guideline gives adding ezetimibe a Class IIa recommendation [12]. That is your starting point for the ezetimibe conversation with your clinician.